Pine Bark (Pycnogenol): Evidence Review of Key Claims
9 April 2026 · 12 min read
This article is for educational and research purposes only. Pycnogenol is a supplement, not a medicine, and is not intended to diagnose, treat, or cure any condition. It may interact with anticoagulants, immunosuppressants, and blood pressure medications. Consult a qualified healthcare practitioner before use, particularly if you are managing a cardiovascular condition, taking prescription drugs, or are pregnant.
French maritime pine trees (Pinus pinaster) grow along the Atlantic coast of southwest France, a region with distinctive sandy, acidic soil. The bark of these trees has been harvested for a standardised extract since the 1960s, when French chemist Jacques Masquelier first identified oligomeric proanthocyanidins (OPCs) as the key active fraction. The trademarked extract sold as Pycnogenol (produced exclusively by Horphag Research from bark grown in the Les Landes forest) has since accumulated one of the larger proprietary clinical trial databases in the natural products industry.
That database is both the extract's greatest strength and a source of legitimate scepticism. More than 160 published studies exist, yet a significant proportion were funded by the manufacturer, conducted by a small cluster of researchers, and involve modest sample sizes. Understanding which findings hold up to independent scrutiny (and which rely entirely on industry-backed data) is the central challenge for anyone evaluating this extract.
What Pycnogenol Contains: OPCs and Beyond
Pycnogenol is a concentrated mixture of polyphenolic compounds. The dominant components are oligomeric proanthocyanidins (chains of catechin and epicatechin units linked together) along with monomeric catechins (catechin and taxifolin), phenolic acids (caffeic acid, ferulic acid, p-coumaric acid), and procyanidins of varying chain lengths.
OPCs are not unique to French maritime pine. They appear across the plant kingdom (in grape seeds, bilberry, cranberry, green tea, and cocoa) at varying concentrations and chain-length profiles. Grape seed extract is often compared to Pycnogenol because both are OPC-rich; the two differ in their specific procyanidin profiles and the research behind them.
The standardisation of Pycnogenol guarantees a minimum 65–75% procyanidin content by weight, measured against a catechin reference. This is pharmacologically meaningful: without standardisation, "pine bark extract" products can range from negligible to substantial OPC content with no way to compare them to trial data.
Mechanisms: How OPCs Are Proposed to Work
Nitric Oxide Synthesis and Vasodilation
The most consistently documented mechanism of Pycnogenol is its ability to stimulate endothelial nitric oxide synthase (eNOS), the enzyme responsible for producing nitric oxide (NO) in the lining of blood vessels. NO causes vascular smooth muscle to relax, widening vessel diameter and reducing peripheral resistance. This mechanism is central to Pycnogenol's effects on blood pressure, venous tone, and erectile function.
In vitro work demonstrated that Pycnogenol increased NO production in human endothelial cells at physiologically relevant concentrations. The catechin fraction appears to be the primary driver of eNOS activation, though procyanidins contribute synergistically. This NO-mediated vasodilation is also relevant to the venous insufficiency evidence, where improved venous tone and microcirculation are the proposed therapeutic targets.
Antioxidant Activity
OPCs are potent electron donors, capable of scavenging reactive oxygen species (ROS) directly and of regenerating oxidised vitamin C back to its active form. Pycnogenol has been shown in human studies to increase plasma antioxidant capacity after supplementation, and to reduce markers of oxidative stress including malondialdehyde and 8-isoprostane.
As with most dietary antioxidants, the in vitro antioxidant capacity (measured by assays like ORAC or DPPH) correlates poorly with in vivo outcomes. The antioxidant properties are real but should be treated as one component of mechanism rather than a therapeutic endpoint in themselves.
Anti-Inflammatory Signalling
Pycnogenol inhibits nuclear factor kappa B (NF-κB), the transcription factor that governs expression of pro-inflammatory cytokines including TNF-α, interleukin-1β, and interleukin-6. This is the same pathway targeted by curcumin and silymarin, and represents a broad-spectrum anti-inflammatory action rather than a highly specific one.
Pycnogenol also inhibits cyclooxygenase-1 and -2 (COX-1 and COX-2) enzymes to a modest degree, contributing to reduced prostaglandin synthesis. This partially explains clinical observations of reduced pain in osteoarthritis trials.
Collagen and Extracellular Matrix Support
Pycnogenol binds directly to collagen and elastin fibres, and has been shown to inhibit collagenase and elastase, the enzymes that degrade connective tissue. This matrix-protective activity is mechanistically relevant to both vascular health (venous wall integrity) and skin appearance (dermal collagen preservation).
Where the Evidence Is Strong: Chronic Venous Insufficiency
Chronic venous insufficiency (CVI) is characterised by leg oedema, heaviness, pain, and in severe cases venous ulcers. It represents the most thoroughly studied application of Pycnogenol. Multiple randomised controlled trials, some independent of the manufacturer, have examined this indication.
A double-blind RCT published in Fitoterapia enrolled 40 patients with CVI and varicosities, randomising them to Pycnogenol 100 mg three times daily or placebo for two months. Treatment produced significant reductions in subcutaneous oedema, leg heaviness, and pain at both 30 and 60 days compared to placebo (PMID 10844161).
A larger prospective controlled study involving 98 subjects compared Pycnogenol 150 mg/day, elastic compression stockings alone, and combination therapy over eight weeks. All three groups improved, with the combination group showing significantly greater reductions in ankle circumference, resting blood flow measurements, and symptom scores than either intervention alone. This is a pragmatically useful finding: Pycnogenol appears to work additively with compression rather than replacing it.
The mechanistic basis (eNOS-mediated improvement in venous tone and reduction of endothelial permeability) is biologically plausible and supported by ex vivo work on human venous segments showing dose-dependent improvements in venous contractility.
Verdict: CVI is the most convincing application. Multiple trials, a coherent mechanism, and clinically meaningful endpoints. The effect size is modest rather than dramatic, and Pycnogenol should be viewed as an adjunct to, not a replacement for, compression therapy.
Blood Pressure: Meta-Analytic Evidence with Caveats
A 2025 systematic review and meta-analysis published in BMC Complementary Medicine and Therapies pooled 27 randomised controlled trials with 1,685 participants and found statistically significant reductions in both systolic and diastolic blood pressure, alongside improvements in other cardiometabolic markers (doi:10.1186/s12906-025-04819-9).
The reported reductions were modest: approximately 2.3 mmHg systolic and 2.6 mmHg diastolic, with smaller improvements in fasting blood sugar, HbA1c, body weight, and LDL cholesterol. Effect sizes are small and unlikely to be clinically meaningful as standalone antihypertensive therapy, but the direction of effect is consistent across populations and trial designs.
The mechanism is well-characterised: eNOS activation leads to increased NO bioavailability, causing arterial vasodilation and reduced peripheral resistance. This is a documented pathway, not speculative.
Verdict: Statistically consistent, mechanistically sound, but the effect size is small. Appropriate as an adjunct to diet, exercise, and medical management, not as a replacement.
ADHD: Promising Signal, Limited Evidence Base
The most widely cited Pycnogenol ADHD trial is a 2006 Slovak RCT that enrolled 61 children aged 6–14 with diagnosed ADHD. Participants received Pycnogenol 1 mg/kg/day or placebo for one month. The treatment group showed significant reductions in hyperactivity ratings and improvements in attention as assessed by standardised scales and a visual-motor task. Improvements reversed one month after discontinuation, suggesting the effect is dependent on ongoing supplementation.
This study is genuine and peer-reviewed. However, it has several limitations: one month is short, the sample is small, and no subsequent independent replications in children with ADHD have been published at comparable scale.
A proposed mechanism involves Pycnogenol's ability to reduce urinary catecholamines and lower oxidative stress markers in ADHD children, findings from the same research group. The neurological rationale is plausible but the evidence chain from mechanism to clinical outcome relies heavily on a single trial.
A 2012 Cochrane systematic review examining Pycnogenol across multiple conditions including ADHD concluded that, due to small sample sizes, limited number of trials per condition, and risk of bias, no definitive conclusions regarding efficacy could be drawn.
Verdict: A real signal from a real trial, but insufficient replication to be confident. Mechanistically plausible. Parents researching supplement adjuncts for ADHD may find this worth discussing with a paediatrician, but the evidence does not support strong claims.
Skin Health: Consistent but Industry-Heavy Evidence
Several clinical trials (the majority involving Japanese women and funded or co-authored by Horphag-affiliated researchers) have shown that Pycnogenol supplementation improves objective measures of skin hydration, elasticity, and hyperpigmentation.
Trials in postmenopausal women using 40–100 mg/day over 12 weeks reported increases in skin hydration and elasticity scores alongside self-reported improvements in skin smoothness. Separate work has shown reductions in melasma (facial hyperpigmentation) at doses of 25 mg three times daily over 30 days.
The collagenase and elastase inhibition and UV-protective antioxidant effects provide mechanistic plausibility. Pycnogenol's ability to stimulate hyaluronic acid synthesis in skin fibroblasts adds another pathway for improved hydration.
The main limitation is the near-total reliance on industry-connected research. Independent replication in skin outcomes is sparse.
Verdict: Biologically plausible and supported by consistent trial data, but the near-total absence of independent replication warrants caution. Skin benefits are likely real but probably modest.
Asthma and Allergic Respiratory Conditions
Pycnogenol inhibits the synthesis of leukotriene B4, a potent pro-inflammatory lipid mediator central to allergic bronchoconstriction. Several small trials have examined this in asthmatic populations.
A 2004 RCT enrolled 26 mild-to-moderate asthmatic adults and found that Pycnogenol 200 mg/day for four weeks reduced leukotrienes in urine and improved lung function scores compared to placebo, with significant reductions in rescue inhaler use.
However, as with ADHD, the asthma evidence base is built almost entirely on small, single studies. The 2012 Cochrane review reached the same conclusion here as across all other indications: sample sizes are insufficient to draw reliable conclusions.
Verdict: Mechanistically interesting, with early clinical signals. Not a replacement for inhaled corticosteroids or bronchodilators. A potential adjunct in well-controlled mild asthma, but the evidence is too thin for confident recommendations.
Standardised Pycnogenol vs Generic Pine Bark Extract
This distinction matters practically. All the clinical trials discussed above used the trademarked Pycnogenol extract (standardised to a specific procyanidin content, produced from a defined geographic source, and manufactured under controlled conditions). Generic "pine bark extract" products on the Australian market may or may not be equivalent.
The key questions when evaluating a product:
- What is the OPC or procyanidin content? Look for a standardised percentage (typically 65–75%) on the label.
- What is the source? Pinus pinaster bark from Les Landes forest is the studied source. Maritime pine from other regions, or extract from other pine species, may have different phytochemical profiles.
- Is the extract Pycnogenol branded? If not, the manufacturer is not using the proprietary extract studied in trials. That does not mean the product is ineffective, but it means trial results cannot be directly extrapolated.
- Dose form and bioavailability: OPCs are water-soluble and generally well-absorbed. Standard capsule forms are appropriate. There is no published evidence that liposomal or other enhanced forms improve outcomes for pine bark specifically.
For a broader look at how standardisation affects botanical evidence quality, ginkgo biloba offers a comparable case study: the EGb 761 extract underlies virtually all the clinical data, and generic alternatives cannot be assumed equivalent.
Dosage and Practical Considerations
Most CVI trials used 100–150 mg/day. Blood pressure trials typically used 100–200 mg/day. The ADHD study used 1 mg/kg/day in children. Skin and asthma trials used 75–200 mg/day.
A dose of 100–200 mg/day is consistent across the strongest-evidence indications. There is no established benefit from very high doses, and the dose-response relationship has not been thoroughly characterised in humans.
Safety: Pycnogenol has a strong safety profile across trials. The comprehensive 2024 review published in Frontiers in Nutrition covering 39 randomised controlled trials with 2,009 subjects found no serious adverse events attributable to Pycnogenol across supplementation periods of two weeks to six months (PMC11096518). Minor side effects include gastrointestinal discomfort (particularly on an empty stomach), headache, and nausea at higher doses.
Drug interactions: The most clinically significant concern is anticoagulant potentiation. Pycnogenol inhibits platelet aggregation and may enhance the effect of warfarin, clopidogrel, and aspirin. Anyone on anticoagulant or antiplatelet therapy should not self-initiate Pycnogenol without medical oversight. The blood pressure effect is additive with antihypertensive medications, a benefit in some contexts and a hypotension risk in others.
Duration: Most trials of 4–12 weeks duration show effects. CVI management trials suggest ongoing use rather than short courses.
What the Cochrane Review Concluded, and Why It Still Matters
The 2012 Cochrane systematic review examined Pycnogenol across all studied conditions and reached a conclusion that remains relevant: due to small sample sizes, limited numbers of trials per condition, variation in outcomes evaluated, and risk of bias, no definitive conclusions regarding the efficacy or safety of Pycnogenol can be made for any of the conditions.
This is not a condemnation. It is an accurate characterisation of a trial database that was, at the time, numerically large but evidentially thin per condition. Since 2012, the CVI and blood pressure evidence has strengthened modestly through further trials and meta-analyses. The ADHD and asthma evidence remains in essentially the same position.
The Cochrane conclusion is a useful calibration: Pycnogenol is an extract with genuine mechanistic science, consistent signals in some areas, and legitimate clinical application in CVI, but not one with the replicated, large-scale evidence base of pharmaceuticals or even some more extensively studied botanicals.
Key Takeaways
- Pycnogenol is a standardised extract of French maritime pine bark, concentrated in OPCs and phenolic acids.
- Its primary documented mechanisms are eNOS-mediated NO production, NF-κB inhibition, antioxidant activity, and connective tissue matrix support.
- Chronic venous insufficiency is the strongest evidence area: multiple RCTs, coherent mechanism, clinically meaningful endpoints.
- Blood pressure shows small but consistent reductions in meta-analysis.
- ADHD and asthma have real but under-replicated signals from single trials.
- Skin health evidence is consistent but heavily industry-funded.
- Generic pine bark extracts are not equivalent to the studied Pycnogenol formulation; standardisation matters.
- Key safety consideration: avoid combining with anticoagulants without medical supervision.